An interventional study of HeartLogic in Heart Failure, sponsored by Tor Biering-Sørensen. Recruiting at 5 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Tor Biering-Sørensen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.
Among the 242 studies in Heart Failure with a site in Denmark, this one is the 42nd largest by planned enrollment of the 187 interventional ones that give a count, is one of 17 that started in 2024, is one of 89 with no phase, reaches primary completion later than 28 of the 59 other live ones, and was the 203rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark, Finland, Norway and 1 more country
Ages 18–99
University of Aarhus · Sites in Denmark
Ages 18+
Novo Nordisk A/S · Sites in Denmark, United States, Argentina and 24 more countries
Ages 18+
Gødstrup Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
242 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 39 · Phase 3 43 · Phase 4 15
First in 1983; this study’s year is marked. 17 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,428 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 197 across the 187 interventional studies, 213 across the 54 observational. Of the 159 that completed or were terminated, 55 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 242 have an industry lead sponsor. The 10 most frequent:
Tor Biering-Sørensen is the lead sponsor of 22 studies on the registry; 11 are open to participants now.
Tor Biering-Sørensen has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04709900Copenhagen University Hospital, RigshospitaletCT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes | 2026-12 |
| NCT05104658Center for Clinical Research and PreventionHeart Rehabilitation for All | 2026-12-31 |
| NCT05063955Aarhus University HospitalMechanism of Sarcopenia in Heart Failure | 2026-12-31 |
| NCT05276219Copenhagen University Hospital, RigshospitaletDECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure | 2027-05-01 |
| NCT05834803University of AarhusEffects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients. | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 242 studies in Heart Failure with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the impact of HeartLogic-guided management on clinical outcomes among patients implanted with an eligible cardiac device.
The study is a pragmatic, registry-based, randomized controlled trial. Eligible patients in Denmark will be randomized 1:1 to either HeartLogic-guided management or usual care. During the trial, patients in the HeartLogic arm will be contacted by the study team in case of any HeartLogic alerts for evaluation and treatment decisions. There will be no mandatory in-person visits scheduled in the trial. HeartLogic alerts will be managed according to a prespecified management guide. Trial data besides device-related data will be retrieved from the Danish nationwide health registries including baseline information and endpoint data. The control group will receive usual HF care in the Danish health system without the involvement of the study team. The study will comply with the standards of the CONSORT statement and the principles of the Declaration of Helsinki.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There are no specific exclusion criteria for the trial.
HeartLogic alerts will be transmitted to the study team, which will subsequently contact the participant to assess any treatment needs. Treatment needs will be assessed according to current clinical practice guidelines.
Other: HeartLogic
The control group will receive usual HF care in the Danish health system.
HeartLogic alerts will be managed according to a standardized alert management guide to ensure uniform reactions to HeartLogic alerts.
Composite endpoint of hospitalization for heart failure or all-cause death (first event)
Time frame: 42 months
Composite endpoint of hospitalization for heart failure or all-cause death (recurrent events)
Time frame: 42 months
Hospitalization for heart failure (first event)
Time frame: 42 months
All-cause hospitalization
Time frame: 42 months
All-cause mortality
Time frame: 42 months
Hospitalizations for heart failure (recurrent events)
Time frame: 42 months
Hierarchical composite of all-cause mortality, total number of heart failure hospitalizations, and total number of all-cause hospitalizations
Time frame: 42 months
All-cause readmission within 30 days after hospitalization for heart failure
Time frame: 42 months
Hospitalization for any cardiovascular disease
Time frame: 42 months
Hospitalization for any cardio-respiratory disease
Time frame: 42 months
Hospitalization for atrial fibrillation
Time frame: 42 months
Atrial fibrillation burden
Time frame: 42 months
Hospitalization for cardiac arrest
Time frame: 42 months
Ventricular tachyarrhythmia leading to anti-tachycardia pacing and/or shock
Time frame: 42 months
Cardiovascular mortality
Time frame: 42 months
Incident heart failure (among participants without heart failure at baseline)
Time frame: 42 months
Days alive and out of hospital
Time frame: 42 months
Length of hospital stay
Time frame: 42 months
Use of guideline-directed medical therapy for heart failure
Time frame: 42 months
HeartLogic alert rate
Time frame: 42 months
Average HeartLogic index
Time frame: 42 months
Median HeartLogic alert length
Time frame: 42 months
% time in HeartLogic alert
Time frame: 42 months
Maximal observed HeartLogic index
Time frame: 42 months
Time from HeartLogic alert to clinical event
Time frame: 42 months
Individual HeartLogic sensor trends
Time frame: 42 months
Plan to share: Yes — Data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2027, 42 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 42 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tor Biering-Sørensen